Background: Optimising the selection of HER2-targeted regimens by identifying subsets of HER2-positive breast cancer (BC) patients who need more or less therapy remains challenging. We analysed BC samples before and after treatment with 1 cycle of trastuzumab according to the response to trastuzumab. Methods: Gene expression profiles of pre- and post-treatment tumour samples from 17 HER2-positive BC patients were analysed on the Illumina platform. Tumour-associated immune pathways and blood counts were analysed with regard to the response to trastuzumab. HER2-positive murine models with differential responses to trastuzumab were used to reproduce and better characterise these data. Results: Patients who responded to single-agent trastuzumab...
INTRODUCTION: The clinical efficacy of trastuzumab and taxanes is at least partly related to their a...
<div><p>Intrinsic and acquired resistance to the monoclonal antibody drug trastuzumab is a major pro...
peer reviewedBackground: HER2-positive breast cancers usually contain large amounts of T-cell infilt...
Background: Optimising the selection of HER2-targeted regimens by identifying subsets of HER2-positi...
While results thus far demonstrate the clinical benefit of trastuzumab, some patients do not respond...
While results thus far demonstrate the clinical benefit of trastuzumab, some patients do not respond...
BACKGROUND/AIM:This study sought to determine whether an autoimmune background could identify patien...
HER2-positive tumors comprise 15% to 20% of all breast cancers (BC) and are associated with worse cl...
Growing evidence suggests a clear role of the host immune system in HER2+ breast cancer. In addition...
Understanding the mechanisms of trastuzumab efficacy and resistance is a step toward optimizing trea...
Abstract Background Trastuzumab-based therapies are the therapeutic option for HER2 positive (HER2+)...
The introduction of trastuzumab for anti-HER2 therapy dramatically changed the clinical outcome for ...
BackgroundKRISTINE is an open-label, phase III study of trastuzumab emtansine + pertuzumab (T-DM1 + ...
Disease outcomes of HER2+ breast cancers have dramatically changed after targeted therapies, such as...
The discovery of human epidermal growth factor receptor 2 (HER2) and its role in the biology of brea...
INTRODUCTION: The clinical efficacy of trastuzumab and taxanes is at least partly related to their a...
<div><p>Intrinsic and acquired resistance to the monoclonal antibody drug trastuzumab is a major pro...
peer reviewedBackground: HER2-positive breast cancers usually contain large amounts of T-cell infilt...
Background: Optimising the selection of HER2-targeted regimens by identifying subsets of HER2-positi...
While results thus far demonstrate the clinical benefit of trastuzumab, some patients do not respond...
While results thus far demonstrate the clinical benefit of trastuzumab, some patients do not respond...
BACKGROUND/AIM:This study sought to determine whether an autoimmune background could identify patien...
HER2-positive tumors comprise 15% to 20% of all breast cancers (BC) and are associated with worse cl...
Growing evidence suggests a clear role of the host immune system in HER2+ breast cancer. In addition...
Understanding the mechanisms of trastuzumab efficacy and resistance is a step toward optimizing trea...
Abstract Background Trastuzumab-based therapies are the therapeutic option for HER2 positive (HER2+)...
The introduction of trastuzumab for anti-HER2 therapy dramatically changed the clinical outcome for ...
BackgroundKRISTINE is an open-label, phase III study of trastuzumab emtansine + pertuzumab (T-DM1 + ...
Disease outcomes of HER2+ breast cancers have dramatically changed after targeted therapies, such as...
The discovery of human epidermal growth factor receptor 2 (HER2) and its role in the biology of brea...
INTRODUCTION: The clinical efficacy of trastuzumab and taxanes is at least partly related to their a...
<div><p>Intrinsic and acquired resistance to the monoclonal antibody drug trastuzumab is a major pro...
peer reviewedBackground: HER2-positive breast cancers usually contain large amounts of T-cell infilt...